Eisai Co., Ltd. is a research-based human health care company that discovers, develops and markets products in more than 30 countries. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide health care system. Eisai employs more than 8,000 people worldwide. 

Eisai Submits Application for Additional Indication of Anti-arrhythmic Agent Tambocor(R) Tablets for Tachyarrhythmia in Paediatric Patients in Japan (Jan 14, 2010)

Submission of a New Drug Application for Pancreatic Enzyme Replacement Therapy Agent SA-001 in Japan (Dec 24, 2009)

Eisai Launches New Oral Jelly Formulation of Aricept(R), World's First Oral Jelly for Alzheimer's Disease Treatment (Dec 1, 2009)

Eisai and Quintiles Enter into a Strategic Collaboration to Develop Eisai's Anticancer Compounds (Oct 30, 2009)

Global Phase III Study Results Show Eribulin Meets Primary Endpoint of Overall Survival (Oct 30, 2009)

Eisai and TSD Japan Enter into a License and Joint Development Agreement of Denileukin Diftitox in Japan (Oct 26, 2009)

Eisai Opens Regional Office in Bahrain (Oct 16, 2009)

Abbott and Eisai Submit Application for Approval of Humira(R) for the Treatment of Crohn's Disease in Japan (Sep 30, 2009)

Eisai and DNDi Enter Collaboration and License Agreement to Develop New Drug for Chagas Disease (Sep 29, 2009)

Eisai Submits Application for Additional Indication of its Proton Pump Inhibitor PARIET(R) for Non-erosive GERD in Japan (Sep 29, 2009)

KYORIN and Eisai Sign License Agreement for Development and Marketing of Uritos(R) Tablets in China, India, Sri Lanka and ASEAN Countries (Sep 29, 2009)